Home » Stocks » ArTara Therapeutics

ArTara Therapeutics, Inc. (TARA)

Stock Price: $26.20 USD 1.15 (4.59%)
Updated Aug 4, 2020 3:22 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 153.49M
Revenue (ttm) n/a
Net Income (ttm) -20.35M
Shares Out 5.84M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $26.20
Previous Close $25.05
Change ($) 1.15
Change (%) 4.59%
Day's Open 25.34
Day's Range 24.73 - 26.37
Day's Volume 8,317
52-Week Range 19.22 - 67.08

More Stats

Market Cap 153.49M
Enterprise Value 124.80M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.84M
Float 803,009
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -3.03
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 46,341
Short Ratio 1.32
Short % of Float 2.40%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.33
Revenue n/a
Operating Income -20.66M
Net Income -20.35M
Free Cash Flow -17.72M
Net Cash 28.69M
Net Cash / Share 4.90
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC 8,749.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$47.50*
(81.30% upside)
Low
45.0
Current: $26.20
High
50.0
Target: 47.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue-----2.95--
Gross Profit-----2.95--
Operating Income-15.25-21.37-30.36-28.71-20.87-7.58-7.12-8.00
Net Income-14.99-20.73-29.96-28.53-21.38-3.34-7.91-7.97
Shares Outstanding0.500.450.430.410.410.080.010.01
Earnings Per Share-30.15-45.80-85.20-68.80-52.00-126.40-2,386.40-2,446.40
Operating Cash Flow-15.65-23.23-22.35-23.69-17.57-9.99-6.66-8.23
Capital Expenditures-0.02-0.12-0.04-0.27-0.20-0.050.06-0.03
Free Cash Flow-15.66-23.35-22.39-23.96-17.76-10.04-6.60-8.27
Cash & Equivalents0.5621.8942.1641.3265.2683.605.157.47
Total Debt------3.73-
Net Cash / Debt0.5621.8942.1641.3265.2683.601.437.47
Assets1.2223.5243.9843.5267.5484.805.667.78
Liabilities3.353.089.245.084.132.349.774.15
Book Value-2.1320.4434.7438.4463.4182.46-101-86.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ArTara Therapeutics, Inc.
Country United States
CEO Jesse Shefferman

Stock Information

Ticker Symbol TARA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TARA

Description

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.